160 related articles for article (PubMed ID: 19522163)
1. Clinical utility of diagnostic markers for malignant pleural mesothelioma.
Grigoriu BD; Grigoriu C; Chahine B; Gey T; Scherpereel A
Monaldi Arch Chest Dis; 2009 Mar; 71(1):31-8. PubMed ID: 19522163
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
Pantazopoulos I; Boura P; Xanthos T; Syrigos K
Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
[TBL] [Abstract][Full Text] [Related]
3. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
4. [New diagnostic markers for malignant pleural mesothelioma].
Grigoriu BD; Grégoire M; Chahine B; Scherpereel A
Bull Cancer; 2008 Feb; 95(2):177-84. PubMed ID: 18304902
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
6. [Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].
Scherpereel A; Grigoriu BD; Astoul P
Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S183-90. PubMed ID: 18971844
[TBL] [Abstract][Full Text] [Related]
7. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
8. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
9. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
10. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
11. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Hollevoet K; Reitsma JB; Creaney J; Grigoriu BD; Robinson BW; Scherpereel A; Cristaudo A; Pass HI; Nackaerts K; Rodríguez Portal JA; Schneider J; Muley T; Di Serio F; Baas P; Tomasetti M; Rai AJ; van Meerbeeck JP
J Clin Oncol; 2012 May; 30(13):1541-9. PubMed ID: 22412141
[TBL] [Abstract][Full Text] [Related]
12. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
13. Early stages of mesothelioma, screening and biomarkers.
Klebe S; Henderson DW
Recent Results Cancer Res; 2011; 189():169-93. PubMed ID: 21479901
[TBL] [Abstract][Full Text] [Related]
14. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
15. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
16. Soluble mesothelin-related protein--a blood test for mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789
[TBL] [Abstract][Full Text] [Related]
17. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
[TBL] [Abstract][Full Text] [Related]
18. Current status of screening for malignant pleural mesothelioma.
Pass HI; Carbone M
Semin Thorac Cardiovasc Surg; 2009; 21(2):97-104. PubMed ID: 19822280
[TBL] [Abstract][Full Text] [Related]
19. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for mesothelioma.
Scherpereel A; Lee YC
Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
